PowerPoint Presentation


PRESENTED AT 2021 FALL CLINICAL DERMATOLOGY CONFERENCE, LAS VEGAS, NV, USA, OCTOBER 21–24, 2021

The greater reduction in total PSD score was consistent with improved psoriasis severity and burden 

LS mean change from baseline in BSA was significantly greater with roflumilast at all timepoints

DERMIS-1 DERMIS-2

Reduction in itch occurs as early as Week 2 and consistently improves through Week 8

About 60% of roflumilast-treated patients achieved clear intertriginous skin (I-IGA = 0) at Week 8

The primary endpoint was achieved in both DERMIS-1 and DERMIS-2 (Week 8)

INTRODUCTION
• No nonsteroidal topical therapies with novel mechanism of action for psoriasis have been approved in more than 20 years

– Available topical treatments are less than ideal, necessitating a trade-off between efficacy and tolerability1

• Roflumilast is a selective and highly potent phosphodiesterase-4 inhibitor investigated as a once-daily, nonsteroidal, topical 
treatment for various inflammatory dermatologic conditions
– In a phase 2b, randomized, double-blind, vehicle-controlled trial, roflumilast cream provided 

• Significant and rapid improvement of psoriasis
• Demonstrated efficacy for intertriginous plaques 
• Reduction of itch2

• This poster presents efficacy and safety results from DERMIS-1 (ClinicalTrials.gov Identifier: NCT04211363) and DERMIS-2 
(ClinicalTrials.gov Identifier: NCT04211389) 
– These were 2 identical phase 3, randomized, double-blind, vehicle-controlled studies of once-daily roflumilast cream 0.3% in 

patients with psoriasis (Figure 1)

Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective 
Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials

CONCLUSIONS
Once-daily roflumilast cream 0.3% demonstrated: 
• Clinically meaningful efficacy in psoriasis based on IGA Success at the primary endpoint of 8 weeks

– Results were reproducible across both phase 3 studies
• Significant improvements in difficult-to-treat areas 

– Significant increases in percentages of patients achieving I-IGA Success and I-IGA status of clear
• Superior improvement across multiple other efficacy endpoints versus vehicle cream 

– Onset of efficacy occurred as early as 2 weeks
• In patients with psoriasis, roflumilast cream was well-tolerated with low rates of application-site AEs, treatment-

related AEs, and discontinuations due to AEs, comparable with that of vehicle

Mark Lebwohl,1 Leon H. Kircik,2 Angela Y. Moore,3 Linda Stein Gold,4 James Del Rosso,5 Zoe D. Draelos,6 Melinda J. Gooderham,7 Lawrence J. Green,8 Adelaide A. Hebert,9 Kim A. Papp,10 Jerry Bagel,11 Neal Bhatia,12 Laura K. Ferris,13 Terry Jones,14 Steven E. Kempers,15 David M. Pariser,16
Paul S. Yamauchi,17 Matthew Zirwas,18 Amy Feng,19 Patrick Burnett,19 Robert C. Higham,19 David R. Berk19
1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Icahn School of Medicine at Mount Sinai, New York, NY, Indiana Medical Center, Indianapolis, IN, Physicians Skin Care, PLLC, Louisville, KY, and Skin Sciences, PLLC, Louisville, KY, USA; 3Arlington Research Center, Arlington, TX, Baylor University Medical Center, Dallas, TX, USA; 4Henry Ford Medical Center, Detroit, MI, USA; 5JDR Dermatology Research Center, LLC, Las Vegas, NV, USA; 
6Dermatology Consulting Services, High Point, NC, USA; 7SkiN Centre for Dermatology, Probity Medical Research and Queen’s University, Peterborough, ON, Canada; 8George Washington University School of Medicine, Rockville, MD, USA; 9UT Health McGovern Medical School, Houston, TX, USA; 10Probity Medical Research and K Papp Clinical Research, Waterloo, ON, Canada; 11Psoriasis Treatment Center of Central New Jersey, Windsor, NJ, USA; 
12Therapeutics Clinical Research, San Diego, CA, USA; 13University of Pittsburgh, Department of Dermatology, Pittsburgh, PA, USA; 14U.S. Dermatology Partners Bryan, Bryan, TX, USA; 15Minnesota Clinical Study Center, Fridley, MN, USA; 16Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA; 17David Geffen School of Medicine at UCLA, Los Angeles, and Dermatology Institute & Skin Care Center, Inc., Santa Monica, CA, USA;
18Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA; 19Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA 

Safety
• Roflumilast cream demonstrated low rates of application-site adverse events (AEs), treatment-related AEs, and 

discontinuations due to AEs, comparable with that of vehicle (Table 3)
• There were no treatment-related serious AEs
• Few patients discontinued due to AEs 
• Application-site reactions were low
• Over 96% of patients in each group had no evidence of irritation at Weeks 4 or 8 as assessed by the investigators

METHODS
• The primary endpoint was analyzed using a Cochran-Mantel-Haenszel test stratified by site, baseline Investigator Global 

Assessment (IGA), and baseline intertriginous involvement 
– Statistical significance was concluded at the 5% significance level (2-sided) 
– Missing IGA scores were imputed using multiple imputation 

• To control for multiple comparisons among the secondary endpoints, a multiplicity procedure was used 
– Upon successful testing of the primary endpoint, the α was partitioned to test secondary endpoints 

RESULTS
• 439 patients were enrolled in DERMIS-1 and 442 patients were enrolled in DERMIS-2
• Most patients (86.2% to 91.0%) completed the studies (Table 1)
• Baseline disease characteristics were balanced across treatment groups and similar between the 2 studies (Table 2)

Table 2. Baseline Disease Characteristics (ITT Population)
DERMIS-1 DERMIS-2

Roflumilast Cream 0.3% 
(n=286)

Vehicle 
(n=153)

Roflumilast Cream 0.3% 
(n=290)

Vehicle 
(n=152)

Psoriasis-affected BSA, mean % (SD) 6.3 (4.38) 7.4 (4.76) 7.1 (4.84) 7.7 (5.05)

PASI, mean score (SD) 6.3 (3.15) 6.8 (3.70) 6.5 (3.22) 7.0 (3.52)

WI-NRS, mean score (SD) 5.7 (2.75) 5.7 (2.84) 5.8 (2.61) 6.1 (2.75)

WI-NRS score ≥4, n (%) 218 (76.2) 115 (75.2) 229 (79.0) 116 (76.3)

PSD, mean total score (SD) 72.1 (42.75) 73.4 (41.29) 69.3 (40.66) 77.4 (41.24)

IGA score, n (%)

2 (mild) 51 (17.8) 20 (13.1) 50 (17.2) 24 (15.8)

3 (moderate) 206 (72.0) 122 (79.7) 220 (75.9) 118 (77.6)

4 (severe) 29 (10.1) 11 (7.2) 20 (6.9) 10 (6.6)

I-IGA score, n (%) n=63 n=32 n=53 n=31

2 (mild) 33 (52.4) 16 (50.0) 25 (47.2) 13 (41.9)

3 (moderate) 27 (42.9) 16 (50.0) 27 (50.9) 17 (54.8)

4 (severe) 3 (4.8) 0 1 (1.9) 1 (3.2)

BSA: body surface area; IGA: Investigator Global Assessment; I-IGA: Intertriginous-Investigator Global Assessment; ITT: intent-to-treat; PASI: Psoriasis Area Severity Index; PSD: Psoriasis Symptoms Diary; WI-NRS: 
Worst Itch-Numeric Rating Scale; SD: standard deviation.

Table 1. Patient Disposition
DERMIS-1 DERMIS-2

Patients, n (%)
Roflumilast Cream 0.3% 

(n=286)
Vehicle Cream 

(n=153)
Roflumilast Cream 0.3% 

(n=290)
Vehicle Cream 

(n=152)

Completed 255 (89.2) 133 (86.9) 264 (91.0) 131 (86.2)

Prematurely discontinued 31 (10.8) 20 (13.1) 26 (9.0) 21 (13.8)

Reason for discontinuation

Withdrawal by patient 11 (3.8) 11 (7.2) 10 (3.4) 11 (7.2)

Physician decision 0 1 (0.7) 0 0

Noncompliance 0 0 0 1 (0.7) 

Protocol violation 1 (0.3) 0 0 0

Lost to follow-up 12 (4.2) 4 (2.6) 15 (5.2) 7 (4.6)

Adverse event 5 (1.7) 2 (1.3) 1 (0.3) 2 (1.3)

Pregnancy 1 (0.3) 0 0 0

Other 1 (0.3) 2 (1.3) 0 0

Table 3. Adverse Events 
DERMIS-1 DERMIS-2

n (%)

Roflumilast Cream  
0.3% 

(n=286)
Vehicle Cream 

(n=153)

Roflumilast Cream 
0.3% 

(n=290)
Vehicle Cream  

(n=152)

Patients with any TEAE 72 (25.2) 36 (23.5) 75 (25.9) 28 (18.4)

Patients with any treatment-related TEAE 7 (2.4) 3 (2.0) 16 (5.5) 8 (5.3)

Patients with any serious AE 2 (0.7) 1 (0.7) 0 1 (0.7)

Patients who discontinued study due to AE 5 (1.7) 2 (1.3) 1 (0.3) 2 (1.3)

Most common TEAE (>2% in any group), preferred term 

Hypertensiona 5 (1.7) 6 (3.9) 4 (1.4) 0 

Headache 3 (1.0) 2 (1.3) 11 (3.8) 1 (0.7)

Diarrhea 10 (3.5) 0 8 (2.8) 0

Psoriasis 0 3 (2.0) 1 (0.3) 0

Nasopharyngitis 5 (1.7) 3 (2.0) 1 (0.3) 1 (0.7)
aHypertension includes synonymous terms (eg, blood pressure increased). Data are presented for safety population. AE: adverse event; TEAE: treatment-emergent adverse event.

These 2 phase 3 studies suggest roflumilast cream, an investigational once-daily, nonsteroidal topical phosphodiesterase-4 
inhibitor, has the potential to address many shortcomings of existing topical treatments for plaque psoriasis

REFERENCES
1. Elmets CA, et al. J Am Acad Dermatol 
2021;84:432-470.
2. Lebwohl MG, et al. N Engl J Med 
2020;383:229-239.

ACKNOWLEDGEMENTS
• This study was supported by Arcutis Biotherapeutics, Inc.
• Thank you to the investigators and their staff for their participation in the trial
• We are grateful to the study participants and their families for their time and 

commitment
• Writing support was provided by Christina McManus, PhD, Alligent Biopharm

Consulting LLC, and funded by Arcutis Biotherapeutics, Inc.

DISCLOSURES
ML, LHK, AM, LSG, JDR, ZDD, MJG, LJG, AAH, KAP, JB, NB,
LKF, TJ, SEK, DMP, PSY, and MZ are investigators and/or 
consultants for Arcutis Biotherapeutics, Inc. and received 
grants/research funding and/or honoraria; AF, PB, RCH, 
and DRB are employees of Arcutis Biotherapeutics, Inc. 
Additional disclosures provided on request.

Efficacy
• Both phase 3 studies met the primary endpoint of IGA Success at Week 8 (Figure 2)

– Significantly greater percentages of roflumilast-treated patients achieved IGA Success versus vehicle (Figure 2)
• Roflumilast significantly increased the percentage of patients achieving Intertriginous-Investigator Global Assessment (I-IGA) 

Success and an I-IGA status of clear (Figure 3)

41.9

56.6
62.0

69.4

21.1 21.9

30.6
35.6

0

10

20

30

40

50

60

70

80

90

100

Week 2 Week 4 Week 6 Week 8

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

Roflumilast 0.3% (n=229) Vehicle (n=116)

34.9

50.2
57.8

67.5

22.0
18.0

22.2
26.8

0

10

20

30

40

50

60

70

80

90

100

Week 2 Week 4 Week 6 Week 8

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

Roflumilast 0.3% (n=218) Vehicle (n=115)

Figure 2. Percentages of Patients With IGA Success in DERMIS-1 and DERMIS-2 

IGA Success = Clear or almost clear plus ≥2-grade improvement from baseline. Analyzed using a Cochran-Mantel-Haenszel test stratified by site, baseline IGA, and baseline intertriginous involvement; 
missing scores imputed using multiple imputations. Intent-to-treat population. CI: confidence interval; IGA: Investigator Global Assessment.

(A) (B)

5.9%

20.6%

33.3%

42.4%

2.1% 2.3%
6.1% 6.1%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Week 2 Week 4 Week 6 Week 8

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

Roflumilast 0.3% (n=286) Vehicle (n=153)

3.3%

19.1%
25.6%

37.5%

2.1%
5.8% 4.7%

6.9%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Week 2 Week 4 Week 6 Week 8
%

 o
f P

at
ie

nt
s 

(9
5%

 C
I)

Roflumilast 0.3% (n=290) Vehicle (n=152)

***

*

***
***

***

IGA Success 
DERMIS-1

IGA Success 
DERMIS-2

*P<0.05; **P<0.01;
***P<0.0001

**

Figure 3. Percentages of Patients Achieving I-IGA Success and I-IGA Status of Clear in DERMIS-1 and DERMIS-2

I-IGA Success = Clear or almost clear plus ≥2-grade improvement from baseline. To control for multiple comparisons among the secondary endpoints, a multiplicity procedure was used. Upon successful 
testing of the primary endpoint, the α was partitioned to test secondary endpoints. I-IGA-intent-to-treat population: patients with intertriginous area involvement (I-IGA severity ≥2) at baseline. 
Observed data. CI: confidence interval; I-IGA: Intertriginous-Investigator Global Assessment. 

(A) (B)

34.5

42.3

56.6

71.2

13.3

27.6
22.2

13.8

20.7
28.8

49.1

63.5

24.1

14.8
10.3

0

10

20

30

40

50

60

70

80

90

100

Week 2 Week 4 Week 6 Week 8

34.7

52.1
57.8

68.1

6.5

17.9
13.8

18.5

30.6
37.5

42.2

57.4

3.2 10.7 10.3 7.4
0

10

20

30

40

50

60

70

80

90

100

Week 2 Week 4 Week 6 Week 8

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

*

*
**

Roflumilast 0.3% (n=53)
Vehicle (n=31)

**

*** **

Roflumilast 0.3% I-IGA Success  Roflumilast 0.3% I-IGA Clear Vehicle I-IGA Success Vehicle I-IGA Clear 

I-IGA Success and I-IGA Clear 
DERMIS-1

I-IGA Success and I-IGA Clear 
DERMIS-2

Roflumilast 0.3% (n=63)
Vehicle (n=32)
*P<0.05; **P<0.01; 
***P<0.001 for I-IGA Success

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

*P<0.05; **P<0.01;
***P<0.0001

Figure 4. Percentages of Patients Achieving PASI-75 (A, B) and PASI-90 (C, D)

To control for multiple comparisons among the secondary endpoints, a multiplicity procedure was used. Upon successful testing of the primary endpoint, the α was partitioned to test secondary endpoints; 
missing scores imputed using multiple imputations. Intent-to-treat population. Observed data. CI: confidence interval; PASI: Psoriasis Area Severity Index; PASI-75: 75% reduction in PASI total score from 
baseline; PASI-90: 90% reduction in PASI total score from baseline.

Figure 5. Percentages of Patients With WI-NRS Success (≥4-Point Improvement in WI-NRS From Baseline 
Score of ≥4)

To control for multiple comparisons among the secondary endpoints, a multiplicity procedure was used. Upon successful testing of the primary endpoint, the α was partitioned to test secondary 
endpoints; missing scores imputed using multiple imputations. Evaluated in a subset of the intent-to-treat population of patients with WI-NRS pruritus score ≥4 at baseline. Observed data.
CI: confidence interval; WI-NRS: Worst Itch-Numeric Rating Scale.

(A) (B)

***

***

***

***
***

***

**

DERMIS-1 DERMIS-2

**P<0.01; ***P<0.0001

Figure 7. LS Mean Percentage Change From Baseline in Total PSD Score

To control for multiple comparisons among the secondary endpoints, a multiplicity procedure was used. Upon successful testing of the primary endpoint, the α was partitioned to test secondary endpoints.
Evaluated in the intent-to-treat population; analysis of covariance with treatment, site, baseline IGA, baseline intertriginous involvement, and baseline PSD score as independent variables. Observed data. 
CfB: change from baseline; IGA: Investigator Global Assessment; LS: least squares; PSD: Psoriasis Symptom Diary; SE: standard error.

(A) (B)

Baseline Week 2 Week 4 Week 6 Week 8 Baseline Week 2 Week 4 Week 6 Week 8

Baseline Week 2 Week 4 Week 6 Week 8

**

Baseline Week 2 Week 4 Week 6 Week 8

***

Figure 6. LS Mean Percentage Change From Baseline in BSA Affected by Psoriasis

To control for multiple comparisons among the secondary endpoints, a multiplicity procedure was used. Upon successful testing of the primary endpoint, the α was partitioned to test secondary endpoints.
Evaluated in the intent-to-treat population; analysis of covariance with treatment, site, baseline IGA, baseline intertriginous involvement, and baseline BSA as independent variables. 
BSA: body surface area; CfB: change from baseline; LS: least squares; PASI: Psoriasis Area Severity Index; PASI-75: 75% reduction in PASI total score from baseline; PASI-90: 90% reduction in PASI total score 
from baseline; SE: standard error.

(A) (B)

Baseline mean (SD) total PSD score:
Roflumilast 0.3%: 72.1 (42.75) 
Vehicle: 73.4 (41.29)

Baseline mean (SD) total PSD score:
Roflumilast 0.3%: 69.3 (40.66)
Vehicle: 77.4 (41.24)

DERMIS-1 DERMIS-2

***P≤0.0001

LS
 M

ea
n 

%
 C

fB
(S

E)

10

−10

−30

−50

−70

−100

0

−20

−40

−60

−80
−90

LS
 M

ea
n 

%
 C

fB
(S

E)

10

−10

−30

−50

−70

−100

0

−20

−40

−60

−80
−90

100
90
80
70
60
50
40
30
20
10

0

100
90
80
70
60
50
40
30
20
10

0

ENDPOINTS
Primary
• IGA Success at Week 8
Secondary
• I-IGA Success
• PASI-75 and PASI-90
• WI-NRS
• PSD
• BSA
Safety and tolerability

8 weeks dosing visits: 
Weeks 2, 4, 8

ELIGIBILITY

• Diagnosis of plaque 
psoriasis for ≥6 months 
(3 months for children) 

• Age 2+ years
• IGA of at least mild 

severity 

• 2–20% BSA
• PASI ≥2

Roflumilast 
cream 

0.3% QD

Vehicle
QD

Ra
nd

om
iz

e

2:1

N=400+

DERMIS-1 N=439
DERMIS-2 N=442

Figure 1. Study Design

BSA: body surface area; IGA: Investigator Global Assessment; I-IGA: intertriginous-Investigator Global Assessment; PASI: Psoriasis Area and Severity Index; PASI-75: 75% reduction from baseline in 
PASI; PASI-90: 90% reduction from baseline in PASI; PSD: Psoriasis Symptom Diary; QD: once daily; WI-NRS: Worst Itch-Numeric Rating Scale.

2.2
6.1

13.1
22.4

0.7 0.8 1.5
2.3

0
10
20
30
40
50
60
70
80
90

100

Week 2 Week 4 Week 6 Week 8

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

About 40% of patients demonstrated at least a 75% improvement in psoriasis by Week 8

About 20% of roflumilast-treated patients demonstrated at least a 90% improvement

0.7
5.6 8.9

17.0

0.0 0.0 0.0
2.3

0
10
20
30
40
50
60
70
80
90

100

Week 2 Week 4 Week 6 Week 8

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

8.6

21.8
31.3

41.6

1.4
3.0 3.8 7.6

0

20

40

60

80

100

Week 2 Week 4 Week 6 Week 8

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

**

***

***
***

2.6

16.2

28.7

39.0

1.4
3.6

3.9 5.3

0

20

40

60

80

100

Week 2 Week 4 Week 6 Week 8

%
 o

f P
at

ie
nt

s 
(9

5%
 C

I)

***

***

***

DERMIS-1 DERMIS-2

*
**

***

**
**

DERMIS-1 DERMIS-2

*P<0.05; **P<0.01; ***P<0.0001

Percentage of Patients Achieving PASI-75 

Percentage of Patients Achieving PASI-90 
(C)

(B)

(D)

**

(A)

***
***

*** *** *** ***

***

***

• Roflumilast provided statistically superior reduction of psoriasis as indicated by percentages of patients achieving Psoriasis 
Area Severity Index (PASI)-75 and PASI-90 (Figure 4)

• Roflumilast provided significant reduction in itch as indicated by the Worst Itch-Numeric Rating Scale (WI-NRS; Figure 5)
• Roflumilast treatment significantly reduced body surface area affected by psoriasis (Figure 6)

***

• Roflumilast improves disease severity and burden as indicated by significant reductions in the Psoriasis Symptom Diary total 
score (Figure 7)

Roflumilast 0.3% (n=286)                  Vehicle (n=153) Roflumilast 0.3% (n=290)                   Vehicle (n=152)

*P<0.05; **P<0.01; ***P<0.0001

*P<0.05; **P<0.01; ***P<0.0001 *P<0.05; **P<0.01; ***P<0.0001

**P<0.01; ***P<0.0001

Baseline mean (SD) BSA: 
Roflumilast 0.3%: 6.3 (4.38) 
Vehicle: 7.4 (4.76)

Baseline mean (SD) BSA: 
Roflumilast 0.3%: 7.1 (4.84)
Vehicle: 7.7 (5.05)

***
***

***
*** ***

***

**P<0.01; ***P<0.0001 **P<0.01; ***P<0.0001

0

−20

−40

−60

−80

−100

LS
 M

ea
n 

%
 C

fB
(S

E)

0

−20

−40

−60

−80

−100

LS
 M

ea
n 

%
 C

fB
(S

E)

Roflumilast 0.3% (n=286)                  Vehicle (n=153) Roflumilast 0.3% (n=290)                   Vehicle (n=152)

Roflumilast 0.3% (n=286)                  Vehicle (n=153) Roflumilast 0.3% (n=290)                   Vehicle (n=152)

***P≤0.0001


	Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials
















<<
  /ASCII85EncodePages false
  /AllowTransparency false
  /AutoPositionEPSFiles true
  /AutoRotatePages /None
  /Binding /Left
  /CalGrayProfile (Dot Gain 20%)
  /CalRGBProfile (sRGB IEC61966-2.1)
  /CalCMYKProfile (U.S. Web Coated \050SWOP\051 v2)
  /sRGBProfile (sRGB IEC61966-2.1)
  /CannotEmbedFontPolicy /Warning
  /CompatibilityLevel 1.3
  /CompressObjects /Off
  /CompressPages false
  /ConvertImagesToIndexed true
  /PassThroughJPEGImages true
  /CreateJobTicket false
  /DefaultRenderingIntent /Default
  /DetectBlends true
  /DetectCurves 0.0000
  /ColorConversionStrategy /sRGB
  /DoThumbnails false
  /EmbedAllFonts true
  /EmbedOpenType false
  /ParseICCProfilesInComments true
  /EmbedJobOptions true
  /DSCReportingLevel 0
  /EmitDSCWarnings false
  /EndPage -1
  /ImageMemory 1048576
  /LockDistillerParams false
  /MaxSubsetPct 100
  /Optimize true
  /OPM 1
  /ParseDSCComments true
  /ParseDSCCommentsForDocInfo true
  /PreserveCopyPage true
  /PreserveDICMYKValues true
  /PreserveEPSInfo true
  /PreserveFlatness false
  /PreserveHalftoneInfo false
  /PreserveOPIComments false
  /PreserveOverprintSettings true
  /StartPage 1
  /SubsetFonts true
  /TransferFunctionInfo /Apply
  /UCRandBGInfo /Remove
  /UsePrologue false
  /ColorSettingsFile ()
  /AlwaysEmbed [ true
  ]
  /NeverEmbed [ true
  ]
  /AntiAliasColorImages false
  /CropColorImages false
  /ColorImageMinResolution 300
  /ColorImageMinResolutionPolicy /OK
  /DownsampleColorImages true
  /ColorImageDownsampleType /Bicubic
  /ColorImageResolution 600
  /ColorImageDepth -1
  /ColorImageMinDownsampleDepth 1
  /ColorImageDownsampleThreshold 1.00000
  /EncodeColorImages true
  /ColorImageFilter /DCTEncode
  /AutoFilterColorImages true
  /ColorImageAutoFilterStrategy /JPEG
  /ColorACSImageDict <<
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  >>
  /ColorImageDict <<
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  >>
  /JPEG2000ColorACSImageDict <<
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  >>
  /JPEG2000ColorImageDict <<
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  >>
  /AntiAliasGrayImages false
  /CropGrayImages false
  /GrayImageMinResolution 300
  /GrayImageMinResolutionPolicy /OK
  /DownsampleGrayImages true
  /GrayImageDownsampleType /Bicubic
  /GrayImageResolution 600
  /GrayImageDepth -1
  /GrayImageMinDownsampleDepth 2
  /GrayImageDownsampleThreshold 1.00000
  /EncodeGrayImages true
  /GrayImageFilter /DCTEncode
  /AutoFilterGrayImages true
  /GrayImageAutoFilterStrategy /JPEG
  /GrayACSImageDict <<
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  >>
  /GrayImageDict <<
    /QFactor 0.15
    /HSamples [1 1 1 1] /VSamples [1 1 1 1]
  >>
  /JPEG2000GrayACSImageDict <<
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  >>
  /JPEG2000GrayImageDict <<
    /TileWidth 256
    /TileHeight 256
    /Quality 30
  >>
  /AntiAliasMonoImages false
  /CropMonoImages false
  /MonoImageMinResolution 1200
  /MonoImageMinResolutionPolicy /OK
  /DownsampleMonoImages true
  /MonoImageDownsampleType /Bicubic
  /MonoImageResolution 600
  /MonoImageDepth -1
  /MonoImageDownsampleThreshold 1.00000
  /EncodeMonoImages true
  /MonoImageFilter /CCITTFaxEncode
  /MonoImageDict <<
    /K -1
  >>
  /AllowPSXObjects false
  /CheckCompliance [
    /None
  ]
  /PDFX1aCheck false
  /PDFX3Check false
  /PDFXCompliantPDFOnly true
  /PDFXNoTrimBoxError false
  /PDFXTrimBoxToMediaBoxOffset [
    0.00000
    0.00000
    0.00000
    0.00000
  ]
  /PDFXSetBleedBoxToMediaBox false
  /PDFXBleedBoxToTrimBoxOffset [
    0.00000
    0.00000
    0.00000
    0.00000
  ]
  /PDFXOutputIntentProfile (U.S. Web Coated \050SWOP\051 v2)
  /PDFXOutputConditionIdentifier (CGATS TR 001)
  /PDFXOutputCondition ()
  /PDFXRegistryName (http://www.color.org)
  /PDFXTrapped /False

  /CreateJDFFile false
  /Description <<
    /ENU ([Based on 'EPG UPLOAD'] [Based on 'EPG UPLOAD'] [Based on 'HighResolution_NoCrops'] [Based on 'HighResolution_NoCrops'] [Based on 'HighResolution_NoCrops\\0501\\051'] [Based on 'HighResolution_WithCrops'] [Based on '[PDF/X-1a:2001]'] Use these settings to create Adobe PDF documents that are to be checked or must conform to PDF/X-1a:2001, an ISO standard for graphic content exchange.  For more information on creating PDF/X-1a compliant PDF documents, please refer to the Acrobat User Guide.  Created PDF documents can be opened with Acrobat and Adobe Reader 4.0 and later.)
  >>
  /Namespace [
    (Adobe)
    (Common)
    (1.0)
  ]
  /OtherNamespaces [
    <<
      /AsReaderSpreads false
      /CropImagesToFrames true
      /ErrorControl /WarnAndContinue
      /FlattenerIgnoreSpreadOverrides false
      /IncludeGuidesGrids false
      /IncludeNonPrinting false
      /IncludeSlug false
      /Namespace [
        (Adobe)
        (InDesign)
        (4.0)
      ]
      /OmitPlacedBitmaps false
      /OmitPlacedEPS false
      /OmitPlacedPDF false
      /SimulateOverprint /Legacy
    >>
    <<
      /AddBleedMarks false
      /AddColorBars false
      /AddCropMarks false
      /AddPageInfo false
      /AddRegMarks false
      /BleedOffset [
        0
        0
        0
        0
      ]
      /ConvertColors /ConvertToRGB
      /DestinationProfileName (sRGB IEC61966-2.1)
      /DestinationProfileSelector /UseName
      /Downsample16BitImages true
      /FlattenerPreset <<
        /PresetSelector /HighResolution
      >>
      /FormElements false
      /GenerateStructure true
      /IncludeBookmarks false
      /IncludeHyperlinks false
      /IncludeInteractive false
      /IncludeLayers false
      /IncludeProfiles false
      /MarksOffset 0
      /MarksWeight 0.250000
      /MultimediaHandling /UseObjectSettings
      /Namespace [
        (Adobe)
        (CreativeSuite)
        (2.0)
      ]
      /PDFXOutputIntentProfileSelector /DocumentCMYK
      /PageMarksFile /RomanDefault
      /PreserveEditing true
      /UntaggedCMYKHandling /UseDocumentProfile
      /UntaggedRGBHandling /LeaveUntagged
      /UseDocumentBleed false
    >>
    <<
      /AllowImageBreaks true
      /AllowTableBreaks true
      /ExpandPage false
      /HonorBaseURL true
      /HonorRolloverEffect false
      /IgnoreHTMLPageBreaks false
      /IncludeHeaderFooter false
      /MarginOffset [
        0
        0
        0
        0
      ]
      /MetadataAuthor ()
      /MetadataKeywords ()
      /MetadataSubject ()
      /MetadataTitle ()
      /MetricPageSize [
        0
        0
      ]
      /MetricUnit /inch
      /MobileCompatible 0
      /Namespace [
        (Adobe)
        (GoLive)
        (8.0)
      ]
      /OpenZoomToHTMLFontSize false
      /PageOrientation /Portrait
      /RemoveBackground false
      /ShrinkContent true
      /TreatColorsAs /MainMonitorColors
      /UseEmbeddedProfiles false
      /UseHTMLTitleAsMetadata true
    >>
  ]
>> setdistillerparams
<<
  /HWResolution [2400 2400]
  /PageSize [612.000 792.000]
>> setpagedevice